Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.
Carcinogenesis
/ genetics
Carcinoma, Renal Cell
/ genetics
DNA-Binding Proteins
/ genetics
Datasets as Topic
Disease Progression
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Humans
Kidney Neoplasms
/ genetics
Mutation
/ genetics
Neoplasm Staging
Oncogene Proteins, Fusion
/ genetics
Transcription Factors
/ genetics
Transcriptome
Tumor Suppressor Proteins
/ genetics
Ubiquitin Thiolesterase
/ genetics
Von Hippel-Lindau Tumor Suppressor Protein
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 02 2019
27 02 2019
Historique:
received:
25
10
2018
accepted:
28
01
2019
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
24
10
2020
Statut:
epublish
Résumé
Renal cell carcinoma (RCC) subtypes are characterized by distinct molecular profiles. Using RNA expression profiles from 1,009 RCC samples, we constructed a condition-annotated gene coexpression network (GCN). The RCC GCN contains binary gene coexpression relationships (edges) specific to conditions including RCC subtype and tumor stage. As an application of this resource, we discovered RCC GCN edges and modules that were associated with genetic lesions in known RCC driver genes, including VHL, a common initiating clear cell RCC (ccRCC) genetic lesion, and PBRM1 and BAP1 which are early genetic lesions in the Braided Cancer River Model (BCRM). Since ccRCC tumors with PBRM1 mutations respond to targeted therapy differently than tumors with BAP1 mutations, we focused on ccRCC-specific edges associated with tumors that exhibit alternate mutation profiles: VHL-PBRM1 or VHL-BAP1. We found specific blends molecular functions associated with these two mutation paths. Despite these mutation-associated edges having unique genes, they were enriched for the same immunological functions suggesting a convergent functional role for alternate gene sets consistent with the BCRM. The condition annotated RCC GCN described herein is a novel data mining resource for the assignment of polygenic biomarkers and their relationships to RCC tumors with specific molecular and mutational profiles.
Identifiants
pubmed: 30814637
doi: 10.1038/s41598-019-39875-y
pii: 10.1038/s41598-019-39875-y
pmc: PMC6393532
doi:
Substances chimiques
BAP1 protein, human
0
DNA-Binding Proteins
0
Oncogene Proteins, Fusion
0
PBRM1 protein, human
0
Transcription Factors
0
Tumor Suppressor Proteins
0
Von Hippel-Lindau Tumor Suppressor Protein
EC 2.3.2.27
Ubiquitin Thiolesterase
EC 3.4.19.12
VHL protein, human
EC 6.3.2.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2899Subventions
Organisme : NCI NIH HHS
ID : R01 CA223231
Pays : United States
Références
PLoS One. 2013;8(4):e60646
pubmed: 23565265
PLoS One. 2013;8(2):e55871
pubmed: 23409071
Int J Clin Exp Pathol. 2015 May 01;8(5):5435-42
pubmed: 26191247
Cancer Res. 2017 Mar 15;77(6):1271-1282
pubmed: 28126714
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
BMC Bioinformatics. 2005 Sep 14;6:227
pubmed: 16162296
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cancer Immunol Res. 2018 Feb;6(2):127-138
pubmed: 29305520
Cancer Res. 2011 Jan 1;71(1):3-7
pubmed: 21199792
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Immunol Rev. 2017 Mar;276(1):112-120
pubmed: 28258695
BMC Bioinformatics. 2007 Aug 14;8:299
pubmed: 17697349
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6783-8
pubmed: 11371607
J Cell Biochem. 2018 Jun;119(6):4279-4286
pubmed: 29274296
Cell Rep. 2016 May 3;15(5):1088-1099
pubmed: 27117418
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
EBioMedicine. 2016 May;7:62-72
pubmed: 27322459
Bioinformatics. 2013 Jun 15;29(12):1553-61
pubmed: 23613489
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Cancer Immunol Immunother. 2018 Jul;67(7):1031-1040
pubmed: 29541787
Bioinformatics. 2011 Jul 15;27(14):2011-2
pubmed: 21596792
Clin Cancer Res. 2016 Nov 1;22(21):5183-5188
pubmed: 27620276
J Cell Physiol. 2018 Jan;234(1):274-288
pubmed: 30076707
Nature. 2010 Aug 5;466(7307):761-4
pubmed: 20562860
Int J Cancer. 2000 Nov 1;88(3):439-47
pubmed: 11054674
Oncotarget. 2018 Jan 13;9(13):10995-11008
pubmed: 29541392
Clin Transl Med. 2016 Dec;5(1):42
pubmed: 27766604
Exp Nephrol. 2002;10(2):102-13
pubmed: 11937757
Protein Cell. 2018 Mar;9(3):254-266
pubmed: 28108950
Sci Rep. 2017 Aug 17;7(1):8617
pubmed: 28819158
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
J Urol. 2003 Dec;170(6 Pt 1):2163-72
pubmed: 14634372
J Pathol. 2018 Apr;244(5):525-537
pubmed: 29266437
Semin Cell Dev Biol. 2017 Apr;64:98-106
pubmed: 27615548
Immunology. 2010 Apr;129(4):474-81
pubmed: 20201977
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
PLoS Pathog. 2016 Jan 07;12(1):e1005349
pubmed: 26741490
BMC Genomics. 2017 Jul 3;18(1):508
pubmed: 28673244
Mol Cancer Res. 2006 Jan;4(1):39-45
pubmed: 16446405
Nat Immunol. 2014 May;15(5):431-8
pubmed: 24658051
Nat Immunol. 2016 Apr;17(4):387-96
pubmed: 26878112